COMPANY RESEARCHDyne Therapeutics, Inc.
Dyne Therapeutics is a U.S. clinical-stage biotechnology company developing medicines for genetically driven neuromuscular disorders. The company's scientific approach focuses on delivering therapeutic molecules to muscle and related tissues, including oligonucleotide technologies designed to modify disease-associated processes. It works on rare inherited conditions for which delivery to affected tissue is an important challenge in drug development. Based in Waltham, Massachusetts, Dyne is listed on Nasdaq under DYN. Its therapeutic research spans candidate design, delivery-system optimization and clinical evaluation in defined neuromuscular patient populations. Dyne's development strategy is centered on disease biology and the potential benefits of targeted drug delivery.
Company at a glance
Corporate information
- Company entity
- Dyne Therapeutics
- Headquarters / principal office
- Waltham, Massachusetts, United States
Sources (1)
- Primary corporate profile / legal-entity disclosure2026-11-04 retrieval; original page date where stated
- Founded
- 2017
Sources (1)
- Primary corporate profile / legal-entity disclosure2026-11-04 retrieval; original page date where stated
- Ownership / capital status
- Publicly tradedNasdaq-listed: DYN
Sources (1)
- Primary corporate profile / legal-entity disclosure2026-11-04 retrieval; original page date where stated
- Official corporate reference
- https://www.dyne-tx.com/
Sources (1)
- Primary corporate profile / legal-entity disclosure2026-11-04 retrieval; original page date where stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Official corporate website audit2026-11-04 retrieval; original page date where stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Dyne Therapeutics is a U.S. clinical-stage biotechnology company developing medicines for genetically driven neuromuscular disorders. The company's scientific approach focuses on delivering therapeutic molecules to muscle and related tissues, including oligonucleotide technologies designed to modify disease-associated processes. It works on rare inherited conditions for which delivery to affected tissue is an important challenge in drug development. Based in Waltham, Massachusetts, Dyne is listed on Nasdaq under DYN. Its therapeutic research spans candidate design, delivery-system optimization and clinical evaluation in defined neuromuscular patient populations. Dyne's development strategy is centered on disease biology and the potential benefits of targeted drug delivery.
Nasdaq: DYN
targeted oligonucleotide delivery · conjugated medicines
neuromuscular disorders · rare genetic diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
Business, technology & evidence
- Dyne Therapeutics is a U.S. clinical-stage biotechnology company developing medicines for genetically driven neuromuscular disorders. The company's scientific approach focuses on delivering therapeutic molecules to muscle and related tissues, including oligonucleotide technologies designed to modify disease-associated processes. It works on rare inherited conditions for which delivery to affected tissue is an important challenge in drug development. Based in Waltham, Massachusetts, Dyne is listed on Nasdaq under DYN. Its therapeutic research spans candidate design, delivery-system optimization and clinical evaluation in defined neuromuscular patient populations. Dyne's development strategy is centered on disease biology and the potential benefits of targeted drug delivery.
- SecuritiesNasdaq: DYN
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Company-level scope; current candidate stages, financing, site qualifications, and project suitability require separate verification.
- Dyne Therapeutics — official disclosure ↗Dyne Therapeutics · 2026-11-04 retrieval; page undated
- Official issuer and R&D disclosure · Dyne Therapeutics, Inc. ↗Dyne Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Dyne Therapeutics, Inc. ↗Dyne Therapeutics, Inc. ·
- Official issuer and R&D disclosure · Dyne Therapeutics, Inc. ↗Dyne Therapeutics, Inc. ·
- Primary corporate profile / legal-entity disclosure ↗Dyne Therapeutics · 2026-11-04 retrieval; original page date where stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.